NuView Life Sciences, Inc. is a privately held company based in Park City, Utah. NuView is focused on leveraging its proprietary technology developing new molecular imaging biomarkers and targeted therapies for utilization in nuclear medicine. These newly developed diagnostic and therapies for disease addresses the need for improvements for personalized medicine.

NuView, has established a portfolio of IP products currently in development with leading university researchers. These research development programs focus on biomarkers and targeted therapies for cancer and heart disease. These new technologies have the ability to detect the molecular biology of cell-specific changes in gene expression and biochemistry providing the earliest diagnostic information about the nature of a disease, before evolving into a structural change. Early biochemical detection, and alterations to the diagnostitc parent drug may allow for more effective therapy and improved patient outcomes.

NuView has established a pipeline of generic nuclear medicine products available today. These products include radio-diagnostic and radiotherapeutics and pharmaceuticals for cardiology oncology, NuView also markets SPECT and PET molecular imaging cameras and radiopharmaceutical dose delivery systems to generate recurring revenues.